U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Regulatory Information
  3. Search for FDA Guidance Documents
  4. CVM GFI #92 (VICH GL10(R)) Impurities In New Veterinary Drug Substances
  1. Search for FDA Guidance Documents

GUIDANCE DOCUMENT

CVM GFI #92 (VICH GL10(R)) Impurities In New Veterinary Drug Substances November 2007

Download the Final Guidance Document
Final
Docket Number:
FDA-1999-D-0064
Issued by:
Guidance Issuing Office
Center for Veterinary Medicine

This document is intended to provide guidance to registration applicants on the content and qualification of impurities in new veterinary drug substances intended to be used for new veterinary medicinal products, produced by chemical syntheses and not previously registered in a country, region, or member state.  This guidance does not address new veterinary drug substances used during the clinical research stage of development. The following types of new veterinary drug substances are not covered in this guidance: biological/biotechnological, peptide, oligonucleotide, radiopharmaceutical, fermentation products and semi-synthetic products derived therefrom, herbal products, and crude products of animal or plant origin. 

Impurities in new veterinary drug substances are addressed from two perspectives:

  • Chemistry Aspects including classification and identification of impurities, report generation, listing of impurities in specifications, and a brief discussion of analytical procedures; and
  • Safety Aspects including specific guidance for qualifying those impurities that were not present, or were present at substantially lower levels, in batches of a new veterinary drug substance used in safety and clinical studies.

This document does not address: (1) extraneous contaminants that should not occur in new veterinary drug substances and are more appropriately addressed as Good Manufacturing Practice (GMP) issues, (2) polymorphic forms, and (3) enantiomeric impurities.

Submit Comments

Submit Comments Online

You can submit online or written comments on any guidance at any time (see 21 CFR 10.115(g)(5))

If unable to submit comments online, please mail written comments to:

Dockets Management
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852

All written comments should be identified with this document's docket number: FDA-1999-D-0064.

Questions?

Back to Top